Protalix BioTherapeutics, Inc. PLX

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived NYSE

We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. ProCellEx®, our unique, proprietary plant cell-based protein expression system represents a new method for developing recombinant proteins in an industrial-scale manner.

Our corporate strategy includes development of treatments for rare and orphan diseases. To execute on our strategy, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. We believe our treatments of interest will address both genetic and non-genetic diseases. We currently intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities.

Last close 2.55 2026-10-23
Market cap $205.5M 2026-06-30 share count
52-week range 1.65 - 3.19

Valuation FY2025 figures against the last close

P/S3.9x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.08

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $52.7M$53.4M$65.5M$47.6M$38.4M$62.9M$54.7M$34.2M$21.1M$9.2M
Cost of revenue $27.0M$24.3M$23.0M$19.6M$16.3M$10.9M$10.9M$9.3M$15.2M$8.4M
Gross profit $25.8M$29.1M$42.5M$28.0M$22.0M$52.0M$43.8M$24.9M$4.0M$801.0K
R&D $19.6M$13.0M$17.1M$29.3M$29.7M$38.2M$44.6M$33.3M$32.2M$30.4M
SG&A $11.7M$12.2M$15.0M$11.7M$12.7M$11.1M$9.9M$10.9M$11.5M$9.4M
Operating income -$5.5M$3.9M$10.5M-$13.0M-$20.5M$2.7M-$10.7M-$19.3M-$34.5M-$33.2M
Pre-tax income -$5.6M$4.2M$8.6M-$14.4M-$27.6M-$6.5M————
Income tax $996.0K$1.2M$254.0K$530.0K——————
Net income -$6.6M$2.9M$8.3M-$14.9M-$27.6M-$6.5M-$18.3M-$26.5M-$83.4M-$29.4M
EPS, basic -0.080.040.12-0.31-0.62-0.22-1.23———
EPS, diluted -0.080.040.09-0.31-0.62-0.22-1.23-1.80-6.37-0.29
Shares, diluted (wtd. avg.) 78.5M81.1M82.4M48.5M44.1M29.1M14.8M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $14.7M$19.8M$23.6M$17.1M$39.0M$18.3M$17.8M$37.8M$51.2M$63.3M
Receivables $8.8M$2.9M$5.3M$4.6M$3.4M$2.0M$4.7M$4.7M$1.7M$693.0K
Inventory $25.7M$21.2M$19.0M$16.8M$18.0M$13.1M$8.2M$8.6M$7.8M$5.2M
Total current assets $66.7M$60.1M$69.9M$44.9M$61.7M$55.7M$32.5M$53.0M$62.7M$71.9M
Property, plant and equipment $4.9M$4.6M$5.0M$4.6M$5.0M$4.8M$5.3M$6.4M$7.7M$8.7M
Total assets $82.3M$73.4M$84.4M$55.8M$73.7M$67.9M$45.4M$61.1M$72.2M$82.2M
Accounts payable ——$19.6M$12.3M$16.4M$13.9M$11.9M$10.3M$9.3M$7.5M
Total current liabilities $26.5M$25.6M$45.5M$32.4M$33.2M$86.5M$40.2M$25.4M$22.8M$66.2M
Total liabilities $34.1M$30.2M$50.9M$66.4M$79.7M$95.0M$115.7M$114.0M$101.7M$92.2M
Retained earnings -$385.0M-$378.4M-$381.5M-$389.9M-$374.9M-$347.4M-$340.8M-$322.6M-$296.1M-$212.7M
Total equity $48.2M$43.2M$33.6M-$10.6M-$6.0M-$27.0M-$70.3M-$52.9M-$29.5M-$10.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$12.0M$8.7M-$1.3M-$25.0M-$10.3M-$26.1M-$19.4M-$7.7M-$10.0M-$32.1M
Depreciation and amortisation $1.5M$1.3M$1.2M$1.1M$1.1M$1.3M$1.6M$1.7M$1.9M$2.0M
Stock-based compensation $2.3M$3.3M$3.4M$2.1M$2.4M$3.1M$835.0K$514.0K$337.0K$988.0K
Capital expenditure $1.6M$1.3M$1.1M$628.0K$1.5M$655.0K$627.0K$686.0K$971.0K$849.0K
Investing cash flow -$2.4M$4.2M-$16.7M-$5.0M$18.9M-$20.0M-$883.0K-$591.0K-$1.1M-$967.0K
Financing cash flow $9.3M-$16.8M$24.7M$8.2M$12.1M$46.5M$0-$4.8M-$1.4M$19.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-053016.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100M -50M 0 50M 100M Revenue, FY2016: 9.2M Gross profit, FY2016: 801K Net income, FY2016: -29.4M Revenue, FY2017: 21.1M Gross profit, FY2017: 4M Net income, FY2017: -83.4M Revenue, FY2018: 34.2M Gross profit, FY2018: 24.9M Net income, FY2018: -26.5M Revenue, FY2019: 54.7M Gross profit, FY2019: 43.8M Net income, FY2019: -18.3M Revenue, FY2020: 62.9M Gross profit, FY2020: 52M Net income, FY2020: -6.5M Revenue, FY2021: 38.4M Gross profit, FY2021: 22M Net income, FY2021: -27.6M Revenue, FY2022: 47.6M Gross profit, FY2022: 28M Net income, FY2022: -14.9M Revenue, FY2023: 65.5M Gross profit, FY2023: 42.5M Net income, FY2023: 8.3M Revenue, FY2024: 53.4M Gross profit, FY2024: 29.1M Net income, FY2024: 2.9M Revenue, FY2025: 52.7M Gross profit, FY2025: 25.8M Net income, FY2025: -6.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $9.2M $21.1M $34.2M $54.7M $62.9M $38.4M $47.6M $65.5M $53.4M $52.7M
Gross profit $801.0K $4.0M $24.9M $43.8M $52.0M $22.0M $28.0M $42.5M $29.1M $25.8M
Net income -$29.4M -$83.4M -$26.5M -$18.3M -$6.5M -$27.6M -$14.9M $8.3M $2.9M -$6.6M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%